Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07052032
PHASE1

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

Sponsor: Candid Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.

Official title: A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

47

Start Date

2025-06-16

Completion Date

2027-06-01

Last Updated

2026-01-26

Healthy Volunteers

No

Interventions

BIOLOGICAL

CND261

CND261 will be dosed according to the assigned cohort

Locations (6)

Candid Clinical Site

Tbilisi, Georgia

Candid Clinical Site

Chisinau, Moldova

Candid Clinical Site

Auckland, New Zealand

Candid Clinical Site

Bucharest, Romania

Candid Clinical Site

Cluj-Napoca, Romania

Candid Clinical Site

Kyiv, Ukraine